145 related articles for article (PubMed ID: 38744924)
1. Stellae-123 gene expression signature improved risk stratification in taiwanese acute myeloid leukemia patients.
Wang YH; Orgueira AM; Lin CC; Yao CY; Lo MY; Tsai CH; de la Fuente Burguera A; Hou HA; Chou WC; Tien HF
Sci Rep; 2024 May; 14(1):11064. PubMed ID: 38744924
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.
Mosquera Orgueira A; Peleteiro Raíndo A; Díaz Arias JÁ; Antelo Rodríguez B; López Riñón M; Cerchione C; de la Fuente Burguera A; González Pérez MS; Martinelli G; Montesinos Fernández P; Pérez Encinas MM
Front Oncol; 2022; 12():968340. PubMed ID: 36059646
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia.
Tao Y; Wei L; Shiba N; Tomizawa D; Hayashi Y; Ogawa S; Chen L; You H
Mol Biomed; 2024 Jan; 5(1):1. PubMed ID: 38163849
[TBL] [Abstract][Full Text] [Related]
5. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.
Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Grönberg H
Leukemia; 2017 Oct; 31(10):2029-2036. PubMed ID: 28167833
[TBL] [Abstract][Full Text] [Related]
6. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
7. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.
Li Z; Herold T; He C; Valk PJ; Chen P; Jurinovic V; Mansmann U; Radmacher MD; Maharry KS; Sun M; Yang X; Huang H; Jiang X; Sauerland MC; Büchner T; Hiddemann W; Elkahloun A; Neilly MB; Zhang Y; Larson RA; Le Beau MM; Caligiuri MA; Döhner K; Bullinger L; Liu PP; Delwel R; Marcucci G; Lowenberg B; Bloomfield CD; Rowley JD; Bohlander SK; Chen J
J Clin Oncol; 2013 Mar; 31(9):1172-81. PubMed ID: 23382473
[TBL] [Abstract][Full Text] [Related]
8. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
9. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
10. A three-gene signature might predict prognosis in patients with acute myeloid leukemia.
Zhu X; Zhao Q; Su X; Ke J; Yi Y; Yi J; Lin J; Qian J; Deng Z
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32436945
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia.
Park S; Kim YJ; Huh HJ; Chung HS; Lee M; Park YM; Mun YC; Seong CM; Huh J
Hematology; 2021 Dec; 26(1):904-913. PubMed ID: 34789078
[TBL] [Abstract][Full Text] [Related]
12. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
[TBL] [Abstract][Full Text] [Related]
13. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
14. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
[TBL] [Abstract][Full Text] [Related]
15. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
16. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
[TBL] [Abstract][Full Text] [Related]
18. A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Torrebadell M; Díaz-Beyá M; Kalko SG; Pratcorona M; Nomdedeu J; Navarro A; Gel B; Brunet S; Sierra J; Camós M; Esteve J
Leuk Lymphoma; 2018 Oct; 59(10):2394-2404. PubMed ID: 29390924
[TBL] [Abstract][Full Text] [Related]
19. A three-gene expression-based risk score can refine the European LeukemiaNet AML classification.
Wilop S; Chou WC; Jost E; Crysandt M; Panse J; Chuang MK; Brümmendorf TH; Wagner W; Tien HF; Kharabi Masouleh B
J Hematol Oncol; 2016 Sep; 9(1):78. PubMed ID: 27585840
[TBL] [Abstract][Full Text] [Related]
20. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
